Patent US4305870A successfully refreshed from Google Patents.
US4305870A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Intravenous plasma derivatives and their production
Assignee: Oesterreichisches Institut fuer Haemoderivate
•
Filing: 1980-06-13
•
Granted: 1981-12-15
•
Expires: 2000-06-13
Abstract
Abstract Intravenous plasma derivatives having an acceptably lowered content of externally caused deleterious activity or exogenous activity, and their method of production are provided. The method includes the steps of mixing bentonite and an aqueous solution of plasma derivative containing exogenous activity, the bentonite and the mixing time being sufficient to adsorb exogenous activity, and isolating the aqueous phase from the bentonite. Optionally, for the removal of residual exogenous activity, the step of treatment of the aqueous phase with bentonite is repeated and/or the bentonite-treated aqueous phase is further purified by ion-exchange chromatography.
Inventors
- 👤 Daniel T. H. Liu
- 👤 Annita L. S. Weidenbach
- 👤 Rong-Chang Pai
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 23:57
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/644; A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61K39/00; A61K39/395; A61L; A61L2/00; A61L2/16; C07; C07K; C07K1/00; C07K1/14; C07K1/16; C07K1/18; C07K16/00; C07K16/06; C07K16/065; C12N9/6429; C12Y; C12Y304/00; C12Y304/21; C12Y304/21005; C12Y304/21022; A61L2103/00; A61L2103/05; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83; Y10S530/831
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
130 words
A method of producing a plasma derivative selected from the group consisting of immune globulin, plasma protein fraction (PPF), albumin, antihemophilic factor (AHF), prothrombin factor and factor IX concentrate, for intravenous administration, consisting of: (a) mixing bentonite and an aqueous solution of an alcohol fractionated plasma derivative, containing exogenous activity including PKA activity, activated clotting factor, and/or esterase activity, the quantity of bentonite and the mixing time being sufficient to adsorb from at least about the major part of the contained exogenous activity to about substantially all of said exogenous activity (b) separating the aqueous phase from the bentonite with adsorbed exogenous activity (c) subjecting said aqueous phase obtained to treatment with an anion exchange adsorbent, and (d) separating the resulting purified aqueous solution of plasma derivatives from said adsorbent.
Claim 2
Independent Claim
130 words
A method of producing a plasma derivative selected from the group consisting of immune globulin, plasma protein fraction (PPF), albumin, antihemophilic factor (AHF), prothrombin factor and factor IX concentrate, for intravenous administration, consisting of: (a) mixing bentonite and an aqueous solution of an alcohol fractionated plasma derivative, containing exogenous activity including PKA activity, activated clotting factor, and/or esterase activity, the quantity of bentonite and the mixing time being sufficient to adsorb from at least about the major part of the contained exogenous activity to about substantially all of said exogenous activity (b) separating the aqueous phase from the bentonite with adsorbed exogenous activity (c) subjecting said aqueous phase obtained to treatment with an anion exchange adsorbent, and (d) separating the resulting purified aqueous solution of plasma derivatives from said adsorbent.
Claim 3
Dependent Claim
20 words
A method according to claim 1, comprising subjecting the purified solution obtained in step (d) to repeated mixing with bentonite.
Claim 4
Independent Claim
88 words
A method of producing immune globulin for intravenous administration, consisting of: (a) mixing 20 to 30 mg bentonite per ml of 5 to 16% aqueous solution of alcohol fractionated immune globulin, containing exogenous activity including PKA activity, activated clotting factor, and/or esterase activity, for about 30 min. (b) separating the aqueous phase from the bentonite with adsorbed exogenous activity (c) subjecting said aqueous phase obtained to treatment with an anion exchange adsorbent, containing DEAE, and (d) separating the resulting purified aqueous solution of immune globulin from said adsorbent.
Claim 5
Independent Claim
88 words
A method of producing immune globulin for intravenous administration, consisting of: (a) mixing 20 to 30 mg bentonite per ml of 5 to 16% aqueous solution of alcohol fractionated immune globulin, containing exogenous activity including PKA activity, activated clotting factor, and/or esterase activity, for about 30 min. (b) separating the aqueous phase from the bentonite with adsorbed exogenous activity (c) subjecting said aqueous phase obtained to treatment with an anion exchange adsorbent, containing DEAE, and (d) separating the resulting purified aqueous solution of immune globulin from said adsorbent.
Claim 6
Dependent Claim
20 words
A method according to claim 3, comprising subjecting the purified solution obtained in step (d) to repeated mixing with bentonite.
Claim 7
Independent Claim
75 words
A method of producing a pseudomonas immune globulin product for intravenous administration, consisting of: (a) preparing a dilute solution of pseudomonas immune globulin from Cohn cold alcohol fractionated plasma (b) adding bentonite to the solutin of pseudomonas immune globulin with stirring (c) separating the aqueous phase from the bentonite (d) subjecting said aqueous phase obtained to a treatment with DEAE-cellulose and (e) separating the resulting purified aqueous solution of pseudomas immune globulin from said DEAE-cellulose.
Claim 8
Independent Claim
75 words
A method of producing a pseudomonas immune globulin product for intravenous administration, consisting of: (a) preparing a dilute solution of pseudomonas immune globulin from Cohn cold alcohol fractionated plasma (b) adding bentonite to the solutin of pseudomonas immune globulin with stirring (c) separating the aqueous phase from the bentonite (d) subjecting said aqueous phase obtained to a treatment with DEAE-cellulose and (e) separating the resulting purified aqueous solution of pseudomas immune globulin from said DEAE-cellulose.
Claim 9
Dependent Claim
20 words
A method according to claim 5, comprising subjecting the purified solution obtained in step (e) to repeated mixing with bentonite.
References Cited (Backward Citations)
US3083194A
Cited
US3449316A
Cited
US3466368A
Cited
US3664994A
Cited
US3674863A
Cited
US3869436A
Cited
US4100149A
Cited
US4136094A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-12-14 | 1985-06-15 | 1985-12-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-12-14 | 1989-06-15 | 1989-12-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-12-14 | 1993-06-15 | 1993-12-15 | $7700.00 | Window Closed / Lapsed |